加载中
NASDAQHealthcareDrug Manufacturers - Specialty & Generic
最新数据
US$42.81
+US$0.14 · +0.33%
Supernus Pharmaceuticals, Inc. is a biopharmaceutical firm dedicated to developing and marketing therapies for central nervous system (CNS) disorders within the United States. Its portfolio of marketed products includes Trokendi XR, an extended-release topiramate formulation prescribed for both epilepsy management and migraine prevention. Another key product is Oxtellar XR, an extended-release oxcarbazepine designed for the standalone treatment of partial-onset epileptic seizures in patients aged 6 to 17 and adults. The company also offers Qelbree, a selective norepinephrine reuptake inhibitor approved for attention-deficit hyperactivity disorder (ADHD) in children and adolescents aged 6 to 17. For advanced Parkinson's Disease (PD) patients, APOKYN offers acute, intermittent relief during "off" episodes of hypomobility, and XADAGO serves as an adjunctive treatment with levodopa/carbidopa for those experiencing similar off periods. Other offerings include GOCOVRI, which targets dyskinesia in PD patients, and Osmolex ER, used for Parkinson's disease and drug-induced extrapyramidal reactions in adults. MYOBLOC, a Type B toxin, is indicated for cervical dystonia and sialorrhea in adults. Beyond its commercial portfolio, Supernus is actively developing several investigational therapies. These include Qelbree (SPN-812), which has successfully completed Phase III trials for ADHD. SPN-830, a late-stage drug/device combination, aims to prevent off episodes in PD patients. SPN-817 is a novel compound in Phase I trials for severe epilepsy. SPN-820 is undergoing Phase II trials for resistant depression, and SPN-443 and SPN-446 are in earlier, preclinical stages for various CNS indications. Products are distributed through a network of pharmaceutical wholesalers, specialty pharmacies, and authorized distributors. Established in 2005, Supernus Pharmaceuticals is headquartered in Rockville, Maryland.
收盘时
US$42.81
+US$0.14 · +0.33%
盘后
US$42.81
US$0.00 · 0.00%
10月12日 16:38 ET
盘中时间采用ET。市场数据可能有所延迟。
Supernus Pharmaceuticals, Inc. is a biopharmaceutical firm dedicated to developing and marketing therapies for central nervous system (CNS) disorders within the United States. Its portfolio of marketed products includes Trokendi XR, an extended-release topiramate formulation prescribed for both epilepsy management and migraine prevention. Another key product is Oxtellar XR, an extended-release oxcarbazepine designed for the standalone treatment of partial-onset epileptic seizures in patients aged 6 to 17 and adults. The company also offers Qelbree, a selective norepinephrine reuptake inhibitor approved for attention-deficit hyperactivity disorder (ADHD) in children and adolescents aged 6 to 17. For advanced Parkinson's Disease (PD) patients, APOKYN offers acute, intermittent relief during "off" episodes of hypomobility, and XADAGO serves as an adjunctive treatment with levodopa/carbidopa for those experiencing similar off periods. Other offerings include GOCOVRI, which targets dyskinesia in PD patients, and Osmolex ER, used for Parkinson's disease and drug-induced extrapyramidal reactions in adults. MYOBLOC, a Type B toxin, is indicated for cervical dystonia and sialorrhea in adults. Beyond its commercial portfolio, Supernus is actively developing several investigational therapies. These include Qelbree (SPN-812), which has successfully completed Phase III trials for ADHD. SPN-830, a late-stage drug/device combination, aims to prevent off episodes in PD patients. SPN-817 is a novel compound in Phase I trials for severe epilepsy. SPN-820 is undergoing Phase II trials for resistant depression, and SPN-443 and SPN-446 are in earlier, preclinical stages for various CNS indications. Products are distributed through a network of pharmaceutical wholesalers, specialty pharmacies, and authorized distributors. Established in 2005, Supernus Pharmaceuticals is headquartered in Rockville, Maryland.
日内区间
当前US$42.81
52周区间
当前US$42.81
盘中时间采用ET。市场数据可能有所延迟。
Supernus Pharmaceuticals, Inc. is a biopharmaceutical firm dedicated to developing and marketing therapies for central nervous system (CNS) disorders within the United States. Its portfolio of marketed products includes Trokendi XR, an extended-release topiramate formulation prescribed for both epilepsy management and migraine prevention. Another key product is Oxtellar XR, an extended-release oxcarbazepine designed for the standalone treatment of partial-onset epileptic seizures in patients aged 6 to 17 and adults. The company also offers Qelbree, a selective norepinephrine reuptake inhibitor approved for attention-deficit hyperactivity disorder (ADHD) in children and adolescents aged 6 to 17. For advanced Parkinson's Disease (PD) patients, APOKYN offers acute, intermittent relief during "off" episodes of hypomobility, and XADAGO serves as an adjunctive treatment with levodopa/carbidopa for those experiencing similar off periods. Other offerings include GOCOVRI, which targets dyskinesia in PD patients, and Osmolex ER, used for Parkinson's disease and drug-induced extrapyramidal reactions in adults. MYOBLOC, a Type B toxin, is indicated for cervical dystonia and sialorrhea in adults. Beyond its commercial portfolio, Supernus is actively developing several investigational therapies. These include Qelbree (SPN-812), which has successfully completed Phase III trials for ADHD. SPN-830, a late-stage drug/device combination, aims to prevent off episodes in PD patients. SPN-817 is a novel compound in Phase I trials for severe epilepsy. SPN-820 is undergoing Phase II trials for resistant depression, and SPN-443 and SPN-446 are in earlier, preclinical stages for various CNS indications. Products are distributed through a network of pharmaceutical wholesalers, specialty pharmacies, and authorized distributors. Established in 2005, Supernus Pharmaceuticals is headquartered in Rockville, Maryland.
日内区间
当前US$42.81
52周区间
当前US$42.81
盈利能力占已公布营收的百分比。
营收
营业利润
净利润
| 项目（USD） | 2025财年 | 2024财年 | 2023财年 | 2022财年 | 2021财年 |
|---|---|---|---|---|---|
| 营收 | 7.19亿 USD | 6.62亿 USD | 6.08亿 USD | 6.67亿 USD | 5.8亿 USD |
| 销货成本 | 7456.2万 USD | 7790.6万 USD | 8377.9万 USD | 8722.1万 USD | 7506.1万 USD |
| 毛利 | 6.44亿 USD | 5.84亿 USD | 5.24亿 USD | 5.8亿 USD | 5.05亿 USD |
| 研究与开发 | 1.06亿 USD | 1.09亿 USD | 9159.3万 USD | 7455.2万 USD | 9046.7万 USD |
| 销售、一般及管理费用 | 4.86亿 USD | 3.36亿 USD | 3.36亿 USD | 3.77亿 USD | 3.05亿 USD |
| 营业费用 | 6.81亿 USD | 5.02亿 USD | 5.29亿 USD | 5.34亿 USD | 4.19亿 USD |
| 利息收入 | 1325.3万 USD | 1620.4万 USD | 1045.3万 USD | 2168.9万 USD | 1056.9万 USD |
| 利息支出 | — | — | 241.5万 USD | 707万 USD | 2342.3万 USD |
| 折旧和摊销 | 9156.3万 USD | 8041.4万 USD | 8485.9万 USD | 8554.3万 USD | 3259.5万 USD |
| 营业利润 | −3686.4万 USD | 8166.6万 USD | −526.9万 USD | 4612.4万 USD | 8602.9万 USD |
| 净利润 | −3855万 USD | 7386.5万 USD | 131.6万 USD | 6071.1万 USD | 5342.4万 USD |
公司数据更新于 2026年10月13日。
近期已公布业绩
近期已公布业绩
第三方分析师预期可能变化，并非 GoAI 建议。
平均目标
US$57.60
上涨空间 34.55%报告持有此股票敞口的交易所交易基金。
Vanguard Morningstar Total Stock Market ETFVTI7764.47万0.00%2.3万亿 USD0.03%US$381.57-0.10%
iShares Russell 2000 ETFIWM6220.62万0.08%787.4亿 USD0.19%US$277.9-0.37%
Vanguard Morningstar Small-Cap ETFVB5600.45万0.03%1853亿 USD0.03%US$288.16-0.46%
Vanguard Morningstar Small-Cap Value ETFVBR3561.94万0.05%682亿 USD0.05%US$234.71+0.12%
Vanguard Extended Market ETFVXF2975.78万0.03%954亿 USD0.05%US$233.52-0.63%
State Street SPDR Portfolio S&P 600 Small Cap ETFSPSM2279.83万0.14%157.12亿 USD0.03%US$53.42-0.06%
Dimensional - US Small Cap ETFDFAS1952万0.06%338.69亿 USD0.31%US$78.17-0.23%
Dimensional - US Targeted Value ETFDFAT1695.39万0.06%301.22亿 USD0.33%US$67.42+0.22%Vanguard Morningstar Total Stock Market ETFVTIiShares Russell 2000 ETFIWMVanguard Morningstar Small-Cap ETFVBVanguard Morningstar Small-Cap Value ETFVBRVanguard Extended Market ETFVXFState Street SPDR Portfolio S&P 600 Small Cap ETFSPSMDimensional - US Small Cap ETFDFASDimensional - US Targeted Value ETFDFATAI 生成内容及延迟市场数据仅供信息与教育用途，不构成投资建议。
